Culture Expanded MSCs
Mesenchymal Stem Cells (MSCs) are the most commonly used cells in stem cell therapy and regenerative medicine, due to their high and multi-potency. Mesenchymal Stem Cells (MSCs) can be isolated from different tissues in the body.
In this article, you’ll be learning about culture-expanded MSCs, how MSCs can be expanded, The potency of MSCs and the type of cells they can differentiate into.
What are culture expanded Mesenchymal Stem cells?
Mesenchymal stem cells are high potent cells used for cellular therapy and isolated from different parts of the body. Mesenchymal stem cells can be used to improve the patient outcome in diseases and conditions such as autoimmune diseases, degenerative diseases, nerve damage, diabetes mellitus, bone problems etc.
For every patient, millions of mesenchymal stem cells are needed and the exact amount varies according to disease, route of administration, administration frequency, weight, and age of patient.
Mesenchymal stem cells are expanded in a culture media, on a large scale in order to obtain the required quantity of cells needed for cellular therapy.
Culture expanded MSCs: How does it work?
Expanding Mesenchymal stem cells in a media involves step by step process of isolation and expansion.
Mesenchymal Stem Cells Isolation
Mesenchymal stem cells can be isolated from different tissues in the human body such as adipose tissues, dental pulp, human bone marrow, umbilical cord tissue, umbilical cord blood, peripheral blood and synovium.
Mesenchymal stem cells are expanded in culture to increase their yield and amplify their desired functions and potency.
Although the population of Mesenchymal Stem Cells obtained will vary from donor to donor, here are some steps to follow:
· Acquire fresh tissue extracts in strictly aseptic conditions, to maintain purity.
· To remove any cell clusters, you have to filter the cell suspension with a 70-mm filter mesh
· Use a centrifuge to roll the cells for about 5 minutes at 500g
· Suspend the cells again the cells to measure the cell viability and yield using Trypan blue exclusion
· Use in T75 culture dishes to culture the cells in 10 mL of complete MSC medium at a density of 25 × 106 cells/mL. You can then go on to Incubate the plates at 37 °C with 5% CO2 in a humidified chamber without any interruption.
· When it’s past 3 h, remove the non-adherent cells that accumulate on the surface of the dish by changing the medium and replacing it with 10 mL fresh complete medium.
· After an additional 8 h of culture, add 10ml fresh complete medium as a replacement for the existing medium. You’ll have to repeat this step every 8 h for up to 72 h of initial culture.
· Cells can be frozen in MSC growth media plus 10% DMSO (D2650) at a density of 2X106 cells/vial.
Expansion of Mesenchymal Stem Cells in a culture media
Culture expanded mesenchymal cells undergo various stages from the preparation of the culture plate, thawing of Mesenchymal stem cells, and the actual expansion of Mesenchymal stem cells.
The reason behind the cultural expansion of Mesenchymal stem cells is to get them to differentiate into other cell types such as osteoblast, adipocyte, and mesenchymal stromal cells.
In preparation, to expand MSCs in a culture media, you need a culture ware. You can get one plastic or glassware plate and coat it with a sufficient amount of 0.1% gelatin. Don’t forget to aspirate the gelatin solution from the coated plate or flask before you use it.
The next step involves the thawing of the Mesenchymal stem cells, and here are a few steps for you to follow:
After the recommended culture medium and coated culture ware is ready and on standby, remove the vial of Mesenchymal Stem Cells from liquid nitrogen and incubate in a 37C water bath and pay close attention to it, until all the cells are completely thawed. The extent of completely thawed frozen cells and how fast, are what determines the cell viability.
Once the cells have thawed completely, take steps to avoid contamination by disinfecting the walls with 70% ethanol, before you proceed to the next step.
Place the cells in a hood, and carefully transfer the cells to a sterile tube with a pipette (1 or 2ml pipette), Do this in such a way to prevent bubbles.
Then, add drops of Mesenchymal Stem cell expansion medium that have been pre-warmed to 37C to the tube containing the Mesenchymal stem cells.
Be careful to take your time when adding the medium to avoid osmotic shock which could lead to decreased viability.
Proceed to mix the suspension slowly by pipetting up and down two times while avoiding any bubbles.
Place the tube in a centrifuge and centrifuge the tube at 300 x g for 2-3 minutes to roll the cells, and you should not vortex the cells.
After this, then decant as much of the supernatant as possible. These steps are necessary to remove residual cryopreservative (DMSO).
Suspend the cells in a total volume of 10 mL of Mesenchymal Stem Cell Expansion Medium again or any alternative of choice, pre-warmed to 37 °C, containing freshly added 8 ng/mL FGF-2 (F0291).
The next step involves placing the cell suspension onto a 10-cm tissue culture plate or a T75 tissue culture flask.
Maintain the cells in a humidified incubator at 37 °C with 5% CO2.
The next day, exchange the medium with fresh Mesenchymal Stem Cell Expansion Medium (pre-warmed to 37 °C) containing 8 ng/mL FGF-2*. Replace with fresh medium containing FGF-2 every two to three days thereafter.
Isolate the cells when they are approximately 80% confluent, using Trypsin-EDTA and passaged further or frozen for later use.
Expansion of Mesenchymal Stem Cells
Once the cells are actively proliferating and have reached a confluence of approximately 80% (before 100%), you should subculture the cells.
Then remove the medium from the 10-cm tissue culture plate containing the confluent layer of human mesenchymal stem cells, carefully and apply 3-5 mL of Trypsin-EDTA Solution, before proceeding to incubate in a 37 °C incubator for 3-5 minutes.
Crosscheck the culture to see if all the cells are completely detached. Then, add 5 mL Mesenchymal Stem Cell Expansion Medium to the plate.
Swirl the plate mildly to mix the cell suspension. Transfer the separated/isolated cells to a 15 mL conical tube.
Centrifuge the tube at 300 x g for 3-5 minutes to pellet the cells.
Throw the supernatant away and apply 2 mL Mesenchymal Stem Cell Expansion Medium (pre-warmed to 37 °C) containing 8 ng/mL FGF-2 to the conical tube and completely suspend the cells again. Remember not to vortex the cells.
Then, use a hemocytometer to count the number of cells.
Plate the cells at a density of 5,000-6,000 cells per cm2 into the appropriate flasks, plates, or wells in a Mesenchymal Stem Cell Expansion Medium containing 8 ng/mL FGF-2.
Cells can be frozen in MSC growth media plus 10% DMSO (D2650) at a density of 2X106 cells/vial.
Functions of Culture Expanded MSCs
Mesenchymal stem cells are required to be expanded in order for them to be used clinically for therapeutic purposes.
The culture expanded MSCs can be induced to differentiate into adipocytes, osteocytes, hepatocytes, chondrocytes, tenocytes and cardiomyocytes.
Because of its potential to differentiate into different kinds of cells in the body, it can be used to manage liver problems, heart problems, joint and bone problems etc.
Mesenchymal stem cells are also used in tissue regeneration and modulation of the immune system. They possess anti apoptotic, angiogenic, anti fibrotic, and anti-oxidative properties.
However, the quantity of MSCs isolated from body tissues is not enough for clinical and therapeutic applications.
This is why MSCs are expanded in culture to increase their yield for desired therapeutic effect.
- Published in Corporate News / Blog
Why cellular therapies have become a standard in clinics that are betting on biological medicine
Cellular therapy is fast becoming a standard therapy in many regenerative clinics today. Many doctors are no longer questioning the safety and effectiveness of stem cell therapy. This is because various stem cell studies are already describing the benefits of stem cells for patients who are living with chronic and autoimmune health conditions.
This article will be talking about why stem cell therapy have become a standard therapy in clinics, the paracrine effect of stem cells, and other reasons why doctors are adopting stem cells in their clinics.
Benefits of stem cell therapy
Stem cell therapy is an important innovation in medicine because of its regenerative power in the human body. Most disease states are characterized by damaged cells, tissues and organs, which is where stem cell therapy comes in. In stem cell therapy, stem cells are administered into the human body and it replaces the cells damaged by disease or health disorders.
Stem cell research has revealed two major ways of using stem cells to rebuild defective and damaged cells. One of these ways can be seen in procedures like bone marrow transplant, where stem cells are used to replace the damaged cells by engraving, and they then differentiate into the proper cell type. Another mechanism relies on the paracrine effect of stem cells. This procedure of stem cell therapy involves using stem cells isolated from a donor to stimulate the patient’s cells to repair damaged tissues.
Additionally, unlike traditional therapy, stem cells have a wide application. Stem cell therapy is used to manage various degenerative diseases, autoimmune disorders, birth defects, and the research is still ongoing for so many other health conditions where stem cells have shown potential.
Also, there is currently a high demand for aesthetic medicine. Stem cell therapy is a proven alternative to other forms of cosmetology such as plastic surgery. Hence, dermatologists are turning to stem cell therapy to administer anti-aging procedures, skin rejuvenation, hair therapy, micro-needling etc.
The Paracrine effect of stem cells
The paracrine effect of stem cells is one of the most outstanding effects of stem cells. It involves using donor cells to stimulate endogenous repair by harnessing the regenerative power of the human body. It is a mechanism of tissue regeneration that has created new possibilities for managing various conditions using stem cell therapy.
The cells that trigger a paracrine response are; mesenchymal cells, umbilical cord blood, umbilical cord tissue, adipose (fat) tissue and blood cells from a donor’s bone marrow.
The paracrine effect occurs when the donor’s cells send the damaged or defective cells signals to induce self regeneration and repair by secreting some factors and proteins. One of the mechanism by which this paracrine effect is initiated, involves the secretion of cytokines and regulatory proteins by the damaged patient’s cells, these cytokines and proteins act as mediators to stimulate an immune response that attracts the donor cells, this causes the donor cells to release proteins and factors that stimulate the patient’s cells to promote cell proliferation, increase vascularization and blood flow to the areas that needs to heal, while reducing inflammation.
Moreover, research has shown that the paracrine effect of stem cells prevents damaged and diseased cells from dying. They are also therapeutically useful in autoimmune diseases and preventing transplant rejection due to the immune suppression effect they have.
Is stem cell therapy effective?
Doctors are always looking for ways to provide the best possible treatment to their patients, and that is why many clinics are embracing stem cell therapy as a standard, due to its many advantages.
Stem cell therapy is one of the most effective and safest therapy patients can receive, when compared to other existing treatment options. Stem cell therapy is used in promoting patient outcomes in a lot of disease conditions that were previously poorly treated by other alternatives.
Again, as new potentials and ways of applying stem cells are being discovered, doctors are beginning to maximize these benefits in their clinics. Some conditions that are currently treated by stem cells include autoimmune conditions, immunotherapy Car-T cells, chronic obstructive pulmonary disease, neurodegenerative conditions, osteoarthritis, spinal cord injury, aesthetics/anti-aging, sports medicine, autism and multiple sclerosis.
Another reason clinics are adopting stem cell therapy as a standard therapy is because it is easy to administer. A lot of machines such as GCELL {Insert link} which makes the harvesting and processing of stem cells easy and fast, have made the procedures easily adaptable by doctors.
Furthermore, stem cell therapy reduces the treatment and recovery time associated with surgical procedures and other treatment options. This alone is a big factor in why stem cells are becoming a standard therapy in clinics.
Therapeutic uses of stem cells vs traditional medicine
Existing stem cell research has shown how the regenerative effect of stem cells is defining the future of medicine. The major advantage of stem cell therapy over conventional medication-based therapy is its safety. Stem cell therapy is aimed at treating the cause of the disease while traditional medicine targets the symptoms.
Another problem with traditional medical therapy is that it introduces another problem while trying to solve the existing one. As a doctor, you always run the risk of causing harm with each prescription because of various adverse effects that could lead to major organ damage of the kidney, liver etc. On the other hand, patients already know this and they are actively seeking better alternatives, this is why stem cell therapy is fast becoming a standard therapy in clinics.
Moreover, doctors will always be concerned about whether their patients are taking their medications or not. The burden of drug compliance and adherence associated with traditional medical therapy is not always easy to navigate. This is why effective treatment options like stem cell therapy have become a standard therapy in clinics. It only requires the patients having a procedure that repairs and restores damaged cells and tissues in the most natural way.
If you would like to become certified in regenerative medicine using stem cells and other cellular therapy, contact us.
- Published in Corporate News / Blog
Meso Numismatics Closes Global Stem Cell Group Acquisition
LAS VEGAS, NV, August 18, 2021 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, MSSV is pleased to announce that it has closed its acquisition of Global Stem Cells Group. “We are pleased to have finally been able to close on this acquisition,” said David Christensen, President and CEO of MSSV,” We are now well positioned to enter into the growing global Regenerative Medicine industry.”
Global Stem Cells Group (Global) is a premier Regenerative Medicine company that specializes in cutting edge stem cell research, current clinical applications, and physician training. Global licenses its intellectual property and name to medical professionals around the world providing them with necessary equipment and cellular therapy products needed to perform safe and effective Regenerative medicine related treatments. Global has one of the larges physician membership networks in the world with 29 offices in more than 25 countries. The worldwide Regenerative Medicine industry is a multi billion-dollar industry projected to have double digit annual growth rates over the next decade. For more information on Global Stem Cells Group please follow the link www.stemcellsgroup.com
Please read this press release in conjunction with the 8K that was filed today on www.sec.gov.
MSSV has also renegotiated its June 22, 2021 $10.5M financing, of which $8.2M is earmarked for the Lans Holdings Escrow as per the 8k filed June 24th, 2021, as follows: the warrant maturity has been changed to 7 years instead of 3 years and the warrant shall be locked up for the first 2 years whereas during the lock up period the warrant will not be able to be exercised.
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world. With the Company’s breadth of business experience and technology team, the Company will continue to help companies grow. Meso has now added bio-technology to it’s portfolio and will continue to grow the company in this new direction.
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world. With the Company’s breadth of business experience and technology team, the Company will continue to help companies grow.
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Meso Numismatics, Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Meso Numismatics, Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Investor.relations@mssvinc.com
Telephone: (800) 956-3935
- Published in Press Releases
Global Stem Cells Group has Announced an Agreement with Rokit Healthcare
Global Stem Cells Group announces an agreement with the South Korean biotechnology giant known as Rokit Healthcare to represent the company’s technology in the Latin American market.
The Global Stem Cells Group (GSCG) a world leader in Regenerative Medicine Technologies has signed an agreement with South Korean-based Rokit Healthcare, an esteemed bioprinter manufacturer that is committed to advancing the field of regenerative medicine and bettering the quality of life of people around the world.
The field of bioprinting is an extremely new one, but it shows great promise. Simply, it is the automated, computer aided deposition of bio-materials (which are cells, growth factors, and biocompatible polymers) for the manufacturing of functional human tissues or organs. Growth factors are harvested and used with a proprietary printing technology to create or regenerative damaged or diseased organs. Rokit Healthcare does this primarily through the proliferation of a machine that they dub an ‘organ regenerator’– it looks like a 3D printer, but instead of using plastics to create things, they use cells and materials that will be safe to implant within the human body.
The process of 3D bioprinting human tissues and organs is a revolutionary technology in the field of tissue engineering. One of the major challenges in regenerative medicine research and tissue engineering is mimicking the micro and macro environment of human tissues. In response to this challenge, advances in additive manufacturing have inspired scientists in Korea to develop novel bioprinting technology, for human tissues and organs
With the advancements of 3D printing and regenerative medicine working together, the potential is seemingly limitless for the spreading of bioprinting technology, a process that is known as 4D Printing– and Global Stem Cells Group, in an effort make this revolutionary technology available to patients, has forged an agreement with Rokit Healthcare to promote, and distribute the company’s technology in Latin America-
The Invivo 4D Printer is Rokit Healthcare’s flagship product, and it is one that revolutionizes the application of regenerative medicine and growth factor-based therapies. creating a solution for personalized and improved patient care. By leveraging a combination of 3D and bioprinting technologies, it can better distribute a patient’s autologous tissues and cells, making it an invaluable tool for those that are looking to improve the efficacy of their results, especially for certain dermatological conditions including scarring.
“We’re extremely excited about this new opportunity and look forward to working with Rokit,” Says Benito Novas, CEO of the Global Stem Cells Group, “The Invivo 4D Printer is in a position to turn the practice of regenerative medicine onto its head, and we are planning on creating a training center in Cancun, Mexico exclusively to showcase and instruct other physicians in this cutting-edge technology,”
About Global Stem Cells Group
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for regenerative medicine solutions that adhere to the highest medical standards.
About ROKIT :
ROKIT Healthcare is a global healthcare company that is committed to providing an effective and autologous organ regeneration platform. In order to undertake this daunting task, the company uses proprietary biofabrication technologies that show promise in treating several types of diseases in the field of regenerative medicine. Through the proliferation of 4D bioprinting technology, autologous stem cell technologies, ROKIT Healthcare believes that supplying an avenue for organ regeneration will drastically change the way that everyday people trust and manage their own body.
- Published in Press Releases
GLOBAL STEM CELLS GROUP ANNOUNCES THE LAUNCH OF ITS NEW DIVISION “VITA NOVAS”
A Step towards the Actualization of Regenerative Medicine
The Global Stem Cells Group takes another luminary step by launching its new company VITA NOVAS in the field of Regenerative medicine. Vita Novas is a mobile IV infusion company that provides in-home treatments to patients in need of immune modulation to help fight infections, viruses, and diseases. Under the banner of GSCG, Vita Novas is ready to launch in 26 countries in the first year of its inception.
Having the cushion of an already established worldwide network and 10 years of experience of GSCG, VITA NOVAS has already gained ground with the inherited reputation of quality, innovation, and professionalism. The VITA NOVAS’ program delivers micronutrients and stimulating biological products like Exosomes and Mesenchymal Stem Cells intravenously, guaranteeing an effective way for the ingredients to become immediately available to the cells. This greatly decreases the time it takes for the medication or supplements to take effect. Patient-centred carved out packages The Shield, the Fighter, and the Lightening are delivered on-demand to homes, offices, or hotels administered by certified healthcare professionals.
Believing on the percept of Prevent-Protect-Thrive, VITA NOVAS aspires to set standards in the industry, and committed to ensure in-home, and personalized patient service; keeping them away from hospitals and emergencies. VITA NOVAS offers infusion packages, mixed with essential fluids, electrolytes, vitamins, and antioxidants as a powerful cocktail to stimulate the immune system and help bolster it to assist in fighting infections and diseases. In-line with the evolved life pattern of social distancing, the process of treatment at VITA NOVAS culminates as:
Select your Service Area
Schedule a video consultation with our local doctors to discuss your possible treatment plan
Receive the treatment at home
“We have combined elements of Tele-health with cellular therapy, IV wellness infusions, and a direct-to-consumer model intending to capitalize on the burgeoning market for medical services at the patient’s’ place of residence, due to convenience and social distancing practices,” explains Benito Novas , CEO of VITA NOVAS.
The secret behind the VITA NOVAS program is the provision of assistance and prime incentives to medical professionals. Once a physician joins the network, the company provides training and support that they will need in order to set-up run, and market their practices. They enjoy geography and specialization exclusively as well as a strong network of patients referrals, increased revenues, and conduct consultations from home.
Global Stem Cells Group, with golden track record and experience of a decade, is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2010 by Benito Novas, the company combines dedicated researchers, physicians, patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading-edge Regenerative Medicine treatments. Global Stem Cells Groups corporate mission is to make the promise of Regenerative medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art regenerative technology, while adhering to the highest medical standards.
VITA NOVAS can help, to find your service area, please visit: www.vitanovas.net
To know more about the company , visit www.stemcellsgroup.com
- Published in Press Releases
ISSCA to Conduct First Hands On Regenerative Medicine Training after Global Pandemic
he COVID19 pandemic has brought about a ‘new normal’ of social-distancing, closed businesses and self-isolation. After several months of inactivity brought about by this virus and the period of self-isolation, the International Society for Stem Cell Application is ready to begin the process of resuming our schedule of training courses,
Florida (PRUnderground) May 19th, 2020
Now, more than ever, interest in the immune system and its health has breached our collective consciousness, both phycicians and scientist are turning to regenerative medicine as a way to strengthen it. Recent breakthroughs in the field have led to a newly devised program– one with a proprietary protocol for strengthening the immune system, furthering a person’s ability to fight and prevent disease.
This inaugural training will take place in Washington over the course of two days, during which we will be training a group of five doctors in the latest regenerative medicine techniques. We will go over our traditional program providing physicians with all of the tools they will need to begin incorporating regenerative medicine into their own practice
The International Society for Stem Cell Application is an independent, non-profit organization whose objective is to become the gold standard of regenerative medicine. It accomplishes this through hosting conferences and specialized certification courses, publishing and sharing clinical research, and setting protocols in the field of regenerative medicine. Through this partnership, we are seeking to spread knowledge on the current applications of cellular therapies by building a platform for doctors to discuss and debate the newest advancements in the field. These conferences have been held in dozens of countries, and work to create a global network of regenerative medicine researchers and practitioners.
If you’d like to know more information about our program, or the courses that we offer around the world, please check out by visiting our website at: www.issca.us
About International Society for Stem Cells Applications
The International Society for Stem Cells Applications (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology, and the practice of regenerative medicine. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
ISSCA bridges the gaps between scientists and practitioners in Regenerative Medicine. Their code of ethics emphasizes principles of morals and ethical conducts.
At ISSCA, their vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification. ISSCA serves its members through advancements made to the specialty of regenerative medicine. They aim to encourage more physicians to practice regenerative
medicine and make it available to benefit patients both nationally and globally.
For more information, please visit https://www.issca.us/ or send an email to info@stemcellsgroup.com
- Published in Press Releases
GLOBAL STEM CELLS GROUP will host ISSCA Regenerative Medicine Training
After several months of silence due to the mandatory shutdown in place, the training division of Global Stem Cells Group –known as ISSCA Training– has officially announced the reopening of its regularly scheduled training dates Around the world
Miami, FL (PRUnderground) May 20th, 2020
“The future’s looking bright for our Regenerative MedicineTraining program, we’ve taken our course and updated it, reinforcing it with new information and quality protocols that’ll help doctors and their patients manage this ‘new normal’ as well as they can, and we’re very excited to be able to be bringing this new information to physicians around the world– but we’ve decided to start small for now, with the reinstatement of our headquarters’ operations,” — Benito Novas, CEO
Because of the growing interest in the industry , ISSCA Regenerative MedicineTraining has updated its program with new protocols focused on the optimization of the body at the cellular level. Notably, their upcoming June course will also include live practice patients in the treatments of autologous cell therapy, which includes PRP, adipose-derived stem cells, bone-marrow derived stem cells, exosomes, Umbilical Cord Blood Cells, and other novel techniques.
Stem Cell Training is a company that seeks to instruct medical professionals around the world on regenerative medicine techniques. They do this by sharing breakthrough scientific research on stem cell therapy and treatment, as well as developing and offering courses, seminars, and workshops based on this research.
About the Global Stem Cells Group:
Global Stem Cells Group is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2010, the company combines dedicated researchers, physicians ,patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge Regenerative Medicine treatments.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of Regenerative medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art regenerative technology
- Published in Press Releases
Global Stem Cells Group Announces Launch of Vita Novas In-Home IV Infusion Service
Its no secret that a quality IV infusion can boost health and energy. Vita Novas makes this more simple than ever performing IV services than revitalize the body and help it regenerate, right at home.
Miami , Florida (PRUnderground) May 20th, 2020
The interest in boosting the immune system in a safe and effective way is a topic on more minds than ever. In exciting news, Global Stems Group has announced the launch of a new company, Vita Novas who make this both simple and dependable. Vita Novas offers an IV infusion packages are a mix of stem cells, essential fluids, electrolytes, vitamins and antioxidants as a preventive solution for having an optimal immune system. This IV infusion is delivered at home, in an office, or at a hotel, by certified healthcare professionals. With the global pandemic shutting doors of physicians for elective and health-enhancing non-vital procedures going to get IV treatments in most communities is difficult, if not impossible. Vita Novas is opening the doors for these life-enhancing treatments to be accesses in an easy and convenient way.
“The demand for preventive health services using IV infusion is greater than ever,” commented Benito Novas, CEO of the company. “What we are doing, by offering these at home and offices, is not just making things more convenient but also following social distancing requirements. Its truly making the right thing available at the right time and place.”
Vita Novas provides a teleconsultation with a Doctor to determine what meets a patient’s needs best. Three different vitamin and nutrient vitamin infusion packages are available.
The Lighting Package consists of two sessions of IV administration of vitamins (Vitamin C, B-Complex vitamins, and trace minerals), with a patient follow up recommending dietary changes and oral supplements to maintain good health.
The Shield Package is three sessions of IV administered (high dose Vitamin C, Methylcobalamin, Zinc sulphate, Glutathione and five billion flow exosomes). This has been shown have a powerful effect in regulating regenerative processes in the body and increase cell to cell communication. This has been used to treat COVID-19 patients with exciting results, something clearly at the front of people’s minds of all ages and lifestyles.
The Fighter Packages is the platinum offer from Vita Novas. This combines IV administration of high dose micronutrients (amino acids, glutathione), vitamins (B-Complex, methylcobalamin, Folic Acid, Vitamin C), and trace minerals (zinc, copper, magnesium) along with 30 million live stem cells in 5 sessions. This can modulate immunity and assist in the regeneration process of damaged or infected tissue in a very dramatic way.
Vita Novas is currently positioned to be able to launch the program in ten different countries with the number rising to over 25 within six months. The near and far future are bright for the company and its potentially life-changing services.
About the Global Stem Cells Group:
Global Stem Cells Group is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2010, the company combines dedicated researchers, physicians ,patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge Regenerative Medicine treatments.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of Regenerative medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art regenerative technology
- Published in Press Releases
Cellgenic Set to Open New Stem Cells Center in Belgium through Partnership with Churchill Aesthetic Center
The subsidiary of the Global Stem Cells Group seeks to meet the growing demand for patients seeking stem cells treatments across the globe.
MIAMI LAKES, Florida— Cellgenic, a subsidiary of the Global Stem Cells Group (GSCG), has announced that it has signed an agreement that will bring regenerative medical treatments to more patients across Europe with the opening of a new stem cells treatment center in Belgium.
The agreement, signed between the GSCG and Dr. Samy Joheir, owner of Churchill Aesthetic Center (https://www.churchill-aesthetic-center.be/), expands the GSCG’s mission of expanding access to regenerative medicine globally. The agreement opens the center’s doors to patients seeking stem cells treatment options and to physicians across Europe and the Middle East seeking educational opportunities regarding how to incorporate regenerative medicine into their practices. The center is located at 141 Winston Churchill Avenue, B-1180 in Brussels.
The Brussels center will also serve as the GSCG’s head offices and will help the group better serve patients and doctors across Europe and the Middle East.
To new center will officially open on September 30, 2019. In conjunction with the center’s opening, the GSCG and Dr. Joheir will welcome three patients from the Middle East seeking treatments offered by the center. These patients were previously treated in the US prior to the institution of stricter FDA stem cells regulations. The Belgium center will provide these patients with treatment options closer to home, alleviating emotional, financial, and physical stressors in receiving treatment, similar to the group’s current facilities in Cancun that provide critical stem cells treatment to patients traveling from the US.
With the opening of the center, the GSCG also aims to provide more accessible educational facilities and options for physicians in the region looking to receive training in regenerative medicine. The training is in alignment with the services currently offered at the GSCG’s other facilities, such as those located in Cancun for physicians across the Americas.
Over the past few years, the GSCG has sought to achieve its mission in helping to alleviate human suffering by opening stem cells centers across the globe to meet growing patient demands. All of the group’s centers are all currently located outside of the US due to current FDA regulations restricting regenerative medicine products and protocols.
“The Global Stem Cells Group is pleased to be able to reach more patients seeking relief through regenerative medicine with the opening of our Belgian center,” said Benito Novas, CEO of the Global Stem Cells Group. “This expansion will help alleviate travel and financial barriers some European and Middle Eastern patients face in receiving the care they need, now providing them access to a facility closer to home. We are committed to opening up additional treatment centers for both physicians and patients across the globe who may be limited by their local regulations in accessing critical stem cells therapies. Through our facilities, patients looking for relief from regenerative diseases will receive top-notch care in state-of-the-art facilities.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Global Stem Cells Group Set to Conduct Clinical Trials in Miami
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, announced its participation in a new clinical trial in Miami. The trial is sponsored by InGeneron, Inc. and will provide researchers the opportunity to compare two treatment options in patients with partial-thickness rotator cuff tears (PTRCTs). Patient groups will be injected either with a single injection of adipose-derived regenerative cells (ADRCs) or a single corticosteroid injection to examine the efficacy of both treatment protocols.
The study is a prospective, double-blinded, randomized, active-controlled, multi-site, pivotal safety and superior effectiveness study in patients with symptomatic partial-thickness rotator cuff tears. Researchers will compare a single ADRC injection generated with the Transpose® RT system into the supraspinatus tendon and surrounding area to standard-of-care (SOC) corticosteroid injection into the subacromial bursa.
Up to 20 U.S. centers will be initiated to enroll in the study. Two hundred and forty six subjects will be assigned to two randomization arms: an adipose-derived regenerative cell (ADRC) injection arm (ADRC treatment arm) and the SOC corticosteroid injection arm (active control arm). All subjects will be randomly assigned to the ADRC treatment or active control arms in a 2:1 ratio.
The GSCG clinical trial is registered with the US Food and Drug Administration (FDA) and will adhere to all FDA safety protocols. The GSCG will help recruit patients for the study. The goal of the trial is to demonstrate the safety and efficacy of stem cells treatments in helping to treat patients suffering from degenerative diseases and injuries such as PTRCTs.
“The Global Stem Cells Group is committed to helping people across the globe find relief from debilitating diseases and is pleased to serve as a leader in cutting-edge research in the stem cells field,” said Benito Novas, CEO of the Global Stem Cells Group. “This clinical trial will hopefully help us achieve these goals by demonstrating the safety and efficacy of regenerative medicine treatments to physicians, patients, and regulatory bodies so that more patients are able to have access to these treatment protocols and find relief.”
To learn more about the clinical trial, visit https://clinicaltrials.gov/ct2/show/NCT03752827. To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases